Please use this identifier to cite or link to this item:
Title: GRAZAX®: a sublingual immunotherapy vaccine for Hay fever treatment: from concept to commercialization.
Issue Date: 20-Jun-2019
Citation: Hum Vaccin Immunother.2019;(15)12:2887-2895
Abstract: Allergen immunotherapy has been used for more than 100 y, but only recently underlying immunological mechanisms have started to be understood. New Allergy vaccines are now considered to be full pharmaceutical products, that should comply with general as well as specific pharmaceutical legal framework. GRAZAX® is the first global allergy vaccine developed in compliance with the new legal environment and is thus a reference for developing new allergy vaccines. Here, we provide a rationale description of GRAZAX®, providing a sequential description of its pharmaceutical and clinical development. With more than 25 clinical trials, involving more than 8000 patients, including as well three 5-y prospective clinical trials, GRAZAX® is a key product to understand the unique position of allergen-specific immunotherapy as a disease-modifying intervention.
PMID: 31157592
Rights: openAccess
Appears in Collections:Fundaciones e Institutos de Investigación > FIB H. Infantil U. Niño Jesús > Artículos

Files in This Item:
File SizeFormat 
PMC6930101.pdf1.43 MBAdobe PDFView/Open

This item is licensed under a Creative Commons License Creative Commons